Trial · NCT07909473
Group Acupuncture for Pain
NCT07909473, Not applicable, Completed, Duke University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Group Acupuncture for Pain. Trials, record NCT07909473. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07909473
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Group Acupuncture for Pain
- NCT number
- NCT07909473
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 103 participants, actual
- Lead sponsor
- Duke University
- Conditions
- Chronic Pain
- Interventions
- Group Acupuncture Intervention
- First posted
- 2026-11-02
- Last updated
- 2026-11-02
Source ClinicalTrials.gov
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Intervention Acceptability | At completion of study (6 weeks) | We assessed acceptability using the Theoretical Framework of Acceptability (TFA) Questionnaire. 7 TFA constructs are assessed, along with general acceptability items scores. Total score max = 35, with higher scores indicating higher acceptability of healthcare intervention. |
| Primary | Feasibility of Enrollment | Duration of recruitment period, up to approximately 16 months | we will calculate the proportion of people who were approached for study participation and enrolled |
| Primary | Feasibility of Data Collection/Retention | From enrollment to completion of study at 6 weeks | We will calculate the percentage of participants who completed the surveys at each data collection time point (baseline, 3 weeks, 6 weeks) compared to those that did not. |
| Primary | Intervention Fidelity | Duration of recruitment period, up to approximately 16 months | Reported as the proportion (%) of acupuncture sessions attended (out of 10). |
| Primary | Intervention Acceptability Qualitative Interviews | At completion of study (6 weeks) | Interviews were conducted on a subset of participants and included questions assessing participant experiences with the intervention, perceived effectiveness of the intervention, and overall acceptability of the intervention. All interviews were transcribed verbatim, and the transcripts served as the data source. |
| Secondary | Pain Impact | Baseline, 3 weeks, 6 week data collection timepoints | PEG Scale Assessing Pain Intensity and Interference (Pain, Enjoyment, General Activity). Score is calculated by adding the scores of its three questions and dividing the total by three to get an average score from 0 to 10. |
| Secondary | Pain Location | Baseline, 3 weeks, 6 weeks | Pain location (selected on body image); location \& number of pain locations summarized based on participant selection on body map image. |
| Secondary | Neuropathic Pain | Baseline & 6 weeks data collection timepoints | PROMIS Neuropathic Pain Quality. T-score generated, with scores ≥ 50 suggesting a likely or prominent neuropathic pain quality phenotype |
| Secondary | Nociceptive Pain | Baseline and 6-week data collection timepoint | PROMIS Nociceptive Pain questionnaire. T-score generate, with a score \>50 suggesting nociceptive pain involvement. |
| Secondary | Pain Self-Efficacy | Baseline & 6 week data collection timepoint | Pain Self-Efficacy Questionnaire. Scored by adding the numerical ratings of all 10 items, resulting in a total score from 0 to 60. Higher scores indicate greater pain self-efficacy. |
1 to 10 of 17Source ClinicalTrials.gov
See all 17 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07909473
GET https://conductscience.org/api/trials/v1/NCT07909473/registered